Needham analyst David Saxon maintained a Hold rating on Sight Sciences (SGHT – Research Report) today. The company’s shares opened today at $5.72.
According to TipRanks, Saxon is a 3-star analyst with an average return of 3.4% and a 42.68% success rate. Saxon covers the Healthcare sector, focusing on stocks such as Alphatec Holdings, Cooper Co, and Staar Surgical.
Currently, the analyst consensus on Sight Sciences is a Hold with an average price target of $3.88.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $15.30 and a one-year low of $1.04. Currently, Sight Sciences has an average volume of 597.4K.
Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SGHT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sight Sciences (SGHT) Company Description:
Sight Sciences Inc is a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye disease. The company’s product portfolio features the OMNI Surgical System, a dually-indicated device that facilitates the performance of both trabeculotomy and viscoelastic delivery. The company’s non-surgical product portfolio consists of TearCare system which is commercially available for both ophthalmologists and optometrists.
Read More on SGHT:
- Sight Sciences Announces Withdrawal of Final LCDs on Micro-Invasive Glaucoma Surgery from Five Medicare Administrative Contractors
- Sight Sciences (NASDAQ:SGHT) Skyrockets 48% after New Glaucoma News
- Sight Sciences to share results of Sahara RCT vs Restasis with Medicare/payers
- Sight Sciences Announces the Publication of Successful Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease
- Sight Sciences announces acceptance for publication of GEMINI 2 trial
